GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (GREY:BBAGF) » Definitions » Cyclically Adjusted Revenue per Share

BB Biotech AG (BB Biotech AG) Cyclically Adjusted Revenue per Share : $10.74 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is BB Biotech AG Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

BB Biotech AG's adjusted revenue per share for the three months ended in Dec. 2023 was $2.344. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $10.74 for the trailing ten years ended in Dec. 2023.

During the past 12 months, BB Biotech AG's average Cyclically Adjusted Revenue Growth Rate was -4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-15), BB Biotech AG's current stock price is $76.05789. BB Biotech AG's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $10.74. BB Biotech AG's Cyclically Adjusted PS Ratio of today is 7.08.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BB Biotech AG was 7.32. The lowest was 4.88. And the median was 6.76.


BB Biotech AG Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for BB Biotech AG's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG Cyclically Adjusted Revenue per Share Chart

BB Biotech AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 11.24 10.74

BB Biotech AG Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Dec17 Dec18 Dec19 Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.24 10.43 10.39 10.55 10.74

Competitive Comparison of BB Biotech AG's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, BB Biotech AG's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BB Biotech AG's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BB Biotech AG's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BB Biotech AG's Cyclically Adjusted PS Ratio falls into.



BB Biotech AG Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BB Biotech AG's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.344/106.4611*106.4611
=2.344

Current CPI (Dec. 2023) = 106.4611.

BB Biotech AG Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201106 0.000 102.678 0.000
201109 -1.589 101.811 -1.662
201112 1.794 101.408 1.883
201203 3.417 101.826 3.573
201206 2.337 101.596 2.449
201209 14.415 101.392 15.136
201212 -2.494 100.968 -2.630
201303 6.713 101.221 7.061
201306 12.638 101.466 13.260
201309 6.576 101.336 6.909
201312 2.014 101.036 2.122
201403 1.341 101.224 1.410
201406 3.969 101.517 4.162
201409 9.227 101.247 9.702
201412 13.236 100.704 13.993
201503 6.931 100.339 7.354
201506 6.641 100.464 7.037
201509 -10.409 99.785 -11.105
201512 9.239 99.386 9.897
201603 -22.133 99.475 -23.687
201606 0.827 100.088 0.880
201609 7.526 99.604 8.044
201612 -0.403 99.380 -0.432
201703 6.792 100.040 7.228
201706 2.113 100.285 2.243
201712 0.000 100.213 0.000
201812 0.000 100.906 0.000
201912 0.000 101.063 0.000
202012 0.000 100.241 0.000
202103 4.332 100.800 4.575
202106 2.847 101.352 2.991
202112 0.000 101.776 0.000
202203 -5.807 103.205 -5.990
202206 -4.163 104.783 -4.230
202209 4.129 104.835 4.193
202212 -0.657 104.666 -0.668
202303 -4.968 106.245 -4.978
202306 -0.092 106.576 -0.092
202309 -0.832 106.570 -0.831
202312 2.344 106.461 2.344

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


BB Biotech AG  (GREY:BBAGF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

BB Biotech AG's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=76.05789/10.74
=7.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BB Biotech AG was 7.32. The lowest was 4.88. And the median was 6.76.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


BB Biotech AG Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of BB Biotech AG's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BB Biotech AG (BB Biotech AG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (GREY:BBAGF) » Definitions » Cyclically Adjusted Revenue per Share
Traded in Other Exchanges
Address
Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.

BB Biotech AG (BB Biotech AG) Headlines

No Headlines